In world of stem cell research, ‘UC Caucus’ reigns supreme
By David Jensen,
Capitol Weekly
| 06. 21. 2021
They could be called the “UC Caucus,” although that may presume too much. Nonetheless, they come from an institution that has pulled down $1.2 billion from the California state stem cell agency, more than any other enterprise during the last 16 years.
Not to mention that their employer — the University of California — is likely to snag much, much more during the next decade or so.
The “caucus” is composed of the 13 persons with ties to the University of California (UC) who are also members of the governing board of the state’s $12 billion stem cell agency, known officially as the California Institute for Regenerative Medicine(CIRM).
The board is so large, in fact, that at times its board members have outnumbered the CIRM staff.
The UC 13 constitute the largest voting bloc on the CIRM governing board. The “caucus” includes Art Torres, who is a member of the UC Board of Regents and the salaried, vice chairman of the CIRM board of directors. Torres is a well-seasoned, former state politician with decades of vote-counting experience.
The CIRM...
Related Articles
By Roxanne Khamsi, The Atlantic | 07.07.2026
When Ludivine Verboogen and Romain Alderweireldt’s third child was born in Belgium in late 2015, they marveled at his long fingers. Perhaps one day he will be a famous pianist, they thought. But soon Ludivine grew worried that her son...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Michael Le Page , New Scientist | 06.25.2026
We now know the master gene that controls embryonic development in people. Called NANOG, its role has been identified by making precise changes to the DNA of fertilised eggs using a technique called CRISPR base editing.
The discovery might lead...
By Maggie Astor, The New York Times | 06.23.2026
Every year, patients undergo millions of in vitro fertilization procedures worldwide. Only a minority result in a live birth.
In an effort to improve the odds, scientists have developed an array of “add-ons” that could in theory identify the most...
